VEA
AUTL icon

Virtus ETF Advisers’s Autolus Therapeutics AUTL Stock Holding History

Virtus ETF Advisers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,429
Closed -$62.1K – 457
2024
Q4 		$62.1K Buy
26,429
+6,081
+30% +$20.6K 0.03% 438
2024
Q3 		$73.9K Buy
20,348
+364
+2% +$1.45K 0.03% 421
2024
Q2 		$69.5K Buy
+19,984
New +$86.2K 0.03% 433
2022
Q2 		– Sell
-27,536
Closed -$115K – 442
2022
Q1 		$115K Sell
27,536
-1,639
-6% -$6.89K 0.05% 279
2021
Q4 		$151K Buy
+29,175
New +$175K 0.06% 345
2020
Q2 		– Sell
-28,428
Closed -$170K – 451
2020
Q1 		$170K Sell
28,428
-4,149
-13% -$38.4K 0.07% 283
2019
Q4 		$430K Buy
32,577
+16,179
+99% +$212K 0.07% 233
2019
Q3 		$204K Sell
16,398
-913
-5% -$12.1K 0.04% 250
2019
Q2 		$279K Buy
17,311
+8,877
+105% +$199K 0.06% 249
2019
Q1 		$265K Sell
8,434
-1,068
-11% -$30.4K 0.56% 71
2018
Q4 		$312K Buy
+9,502
New +$313K 0.05% 98

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Virtus ETF Advisers's AUTL Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 26,429 shares — an estimated $62.1K sold.

Virtus ETF Advisers first reported a position in AUTL in Q4 2018 and held it in 11 quarters. The position peaked at $430K in Q4 2019. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 26,429 Autolus Therapeutics shares in Q1 2025, an estimated $62.1K.
  • Virtus ETF Advisers first reported a position in Autolus Therapeutics in Q4 2018 and held it in 11 quarters.
  • Virtus ETF Advisers's Autolus Therapeutics position peaked at $430K in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.